DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II]

Author(s): Levy P, Merot JL, Lechat P, Levy E, Bogillot O

Affiliation(s): LEGOS, Universite Paris-Dauphine, Place du Marechal de Lattre de Tassigny, 75775 Paris, France.

Publication date & source: 2001-07, Therapie., 56(4):421-5.

Publication type: Clinical Trial; Clinical Trial, Phase III; English Abstract; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

After a significant mortality benefit with bisoprolol in heart failure was demonstrated in CIBIS-II, an economic evaluation has been performed in cost-effectiveness terms. Average direct costs per patient were based on clinical data from 231 French patients, and measured in the perspective of the French National Health Insurance, effectiveness being expressed in terms of life days gained per patient. The extra cost of bisoprolol treatment and follow-up (averaging FF 1300 per 1.3 years) is outweighed by the reduction in hospitalization costs (representing a saving of FF 10,500 per patient) and other medication costs. Finally, bisoprolol therapy induces benefits in terms of both cost and survival: on average FF 9500 and 11 life days per patient. Sensitivity analyses confirm these results.

Page last updated: 2007-10-18

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017